Amarin (NASDAQ:AMRN – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $32.37 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Amarin Stock Down 0.8 %
Shares of NASDAQ AMRN opened at $0.53 on Monday. The stock has a market capitalization of $217.66 million, a price-to-earnings ratio of -5.89 and a beta of 1.82. The stock’s fifty day simple moving average is $0.56 and its 200 day simple moving average is $0.56. Amarin has a 52-week low of $0.43 and a 52-week high of $1.11.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised Amarin from a “sell” rating to a “hold” rating in a research report on Friday.
Amarin Company Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Stories
- Five stocks we like better than Amarin
- What is Insider Trading? What You Can Learn from Insider Trading
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- How to start investing in penny stocks
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
